Marengoni et al. 2011 — Aging with Multimorbidity A Systematic Review of the Literature

multimorbiditypopulation-agingchronic-diseasesystematic-reviewdisabilityquality-of-careprevalencedemographypublic-healthsurvey

Summary

Systematic review of 41 studies (MEDLINE 1990–2010) on the occurrence, causes, consequences, and care of multimorbidity in the elderly. Prevalence of multimorbidity (2+ concurrent chronic diseases) ranges from 55 to 98% in persons 60+, with older age, female sex, and lower socioeconomic status (SES) as consistent risk factors. Major consequences are disability, poor quality of life, and high health care costs; the effect on mortality is controversial. The evidence base for care of multimorbid patients is essentially absent — clinical guidelines are built for single diseases and may be harmful when applied simultaneously.

Key Claims

Concepts Introduced or Extended

Entities Mentioned

Quotes

"Multimorbidity affects more than half of the elderly population with increasing prevalence in very old persons, women and people from lower social classes."

"We did not find a single study evaluating genetic background, biological causes (such as cholesterol, blood pressure, obesity), life styles (smoking, drinking, nutrition, physical activity), or environmental factors in relation to the development of multimorbidity."

"Adhering to disease-specific clinical guidelines in caring for elderly with multimorbidity may have undesirable effects such as adverse interactions between drugs and diseases."

My Take

A landmark state-of-the-field review that established multimorbidity as a distinct research domain. The most scientifically interesting finding is the controversial mortality result: disease count alone does not reliably predict mortality; disability status mediates or moderates the relationship. This implies that simple count-based multimorbidity is epidemiologically useful for prevalence but clinically insufficient for prognosis — severity and functional status need to be incorporated. The care-quality paradox (more conditions → higher quality scores) is counterintuitive and important: it suggests that the standard quality-indicator framework, built around process compliance with disease-specific guidelines, may be measuring the wrong thing for the most clinically complex patients. The review's explicit exclusion of severity-weighted definitions means all its prevalence and consequence estimates rest on counts, limiting clinical translation. The near-complete absence of evidence on risk factors for multimorbidity — despite its ubiquity — is a striking gap; it reflects the field's youth in 2011 and was a call to action that motivated subsequent work on biological mechanisms.